Tech giants are focusing on using AI in healthcare, with Recursion Pharmaceuticals collaborating with Nvidia

From Nasdaq: 2024-07-04 10:31:40

Tech giants like Google, Microsoft, and Meta are focusing on using AI to disrupt the healthcare sector, with Google unveiling its MedLM suite of healthcare-specific AI models. Nvidia has also announced deals with Johnson & Johnson and GE Healthcare to leverage AI in surgery and medical imaging. Companies like Recursion Pharmaceuticals are integrating AI, machine learning, and automation to discover novel medicines, despite facing financial challenges. Recursion Pharmaceuticals, having recently raised $200 million through an equity offering, is collaborating with Nvidia to accelerate drug discovery processes and shorten timelines. Analysts have a consensus “moderate buy” rating for RXRX stock, with an average target price of $12.83 representing a potential upside of 74.6% from the current value.



Read more at Nasdaq: Should You Buy the Dip in This AI-Driven Drug Stock?